BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 29848778)

  • 1. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.
    Schmitt H; Billmeier U; Dieterich W; Rath T; Sonnewald S; Reid S; Hirschmann S; Hildner K; Waldner MJ; Mudter J; Hartmann A; Grützmann R; Neufert C; Münster T; Neurath MF; Atreya R
    Gut; 2019 May; 68(5):814-828. PubMed ID: 29848778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
    Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
    Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease.
    Li J; Ueno A; Fort Gasia M; Luider J; Wang T; Hirota C; Jijon HB; Deane M; Tom M; Chan R; Barkema HW; Beck PL; Kaplan GG; Panaccione R; Qian J; Iacucci M; Gui X; Ghosh S
    Inflamm Bowel Dis; 2016 Aug; 22(8):1779-92. PubMed ID: 27243594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease.
    Liu C; Xia X; Wu W; Wu R; Tang M; Chen T; Xu F; Cong Y; Xu X; Liu Z
    Clin Exp Immunol; 2013 Jul; 173(1):102-11. PubMed ID: 23607532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease.
    Fang L; Pang Z; Shu W; Wu W; Sun M; Cong Y; Liu Z
    Inflamm Bowel Dis; 2018 Jul; 24(8):1733-1744. PubMed ID: 29718341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intestinal CD14+ Macrophages Protect CD4+ T Cells From Activation-induced Cell Death via Exosomal Membrane TNF in Crohn's Disease.
    Liu H; Liang Z; Wang F; Zheng X; Zeng Z; He X; Gao X; Zhi M; Wu X; Wu X; Lan P
    J Crohns Colitis; 2020 Nov; 14(11):1619-1631. PubMed ID: 32343772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
    Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
    Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of anti-TNF therapy on CD31 and VEGF expression in colonic mucosa of Crohn's disease patients in relation to mucosal healing.
    Eder P; Lykowska-Szuber L; Iwanik K; Krela-Kazmierczak I; Stawczyk-Eder K; Majewski P; Linke K; Kay EW; Wozniak A
    Folia Histochem Cytobiol; 2016; 54(2):75-80. PubMed ID: 27270504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease.
    Agnholt J; Dahlerup JF; Buntzen S; Tøttrup A; Nielsen SL; Lundorf E
    Aliment Pharmacol Ther; 2003 Mar; 17(5):703-10. PubMed ID: 12641520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
    Billiet T; Cleynen I; Ballet V; Claes K; Princen F; Singh S; Ferrante M; Van Assche G; Gils A; Vermeire S
    Scand J Gastroenterol; 2017 Oct; 52(10):1086-1092. PubMed ID: 28622097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.
    ten Hove T; van Montfrans C; Peppelenbosch MP; van Deventer SJ
    Gut; 2002 Feb; 50(2):206-11. PubMed ID: 11788561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients.
    Bassolas-Molina H; Raymond E; Labadia M; Wahle J; Ferrer-Picón E; Panzenbeck M; Zheng J; Harcken C; Hughes R; Turner M; Smith D; Calderón-Gómez E; Esteller M; Carrasco A; Esteve M; Dotti I; Corraliza AM; Masamunt MC; Arajol C; Guardiola J; Ricart E; Nabozny G; Salas A
    Front Immunol; 2018; 9():2307. PubMed ID: 30405600
    [No Abstract]   [Full Text] [Related]  

  • 13. IL-12 and Mucosal CD14+ Monocyte-Like Cells Induce IL-8 in Colonic Memory CD4+ T Cells of Patients With Ulcerative Colitis but not Crohn's Disease.
    Chapuy L; Bsat M; Rubio M; Sarkizova S; Therrien A; Bouin M; Orlicka K; Weber A; Soucy G; Villani AC; Sarfati M
    J Crohns Colitis; 2020 Jan; 14(1):79-95. PubMed ID: 31206576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn's disease.
    Ogino T; Nishimura J; Barman S; Kayama H; Uematsu S; Okuzaki D; Osawa H; Haraguchi N; Uemura M; Hata T; Takemasa I; Mizushima T; Yamamoto H; Takeda K; Doki Y; Mori M
    Gastroenterology; 2013 Dec; 145(6):1380-91.e1. PubMed ID: 23993972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the IL23/IL17 Pathway in Crohn's Disease.
    Schmitt H; Neurath MF; Atreya R
    Front Immunol; 2021; 12():622934. PubMed ID: 33859636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profoundly Expanded T-cell Clones in the Inflamed and Uninflamed Intestine of Patients With Crohn's Disease.
    Doorenspleet ME; Westera L; Peters CP; Hakvoort TBM; Esveldt RE; Vogels E; van Kampen AHC; Baas F; Buskens C; Bemelman WA; D'Haens G; Ponsioen CY; Te Velde AA; de Vries N; van den Brink GR
    J Crohns Colitis; 2017 Jul; 11(7):831-839. PubMed ID: 28158397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease.
    Kanai T; Watanabe M; Okazawa A; Nakamaru K; Okamoto M; Naganuma M; Ishii H; Ikeda M; Kurimoto M; Hibi T
    Gastroenterology; 2000 Dec; 119(6):1514-23. PubMed ID: 11113073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
    Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
    Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.
    Di Sabatino A; Ciccocioppo R; Cinque B; Millimaggi D; Morera R; Ricevuti L; Cifone MG; Corazza GR
    Gut; 2004 Jan; 53(1):70-7. PubMed ID: 14684579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
    Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
    Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.